Clinical trial

Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment

NCT00105417 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed

Key facts

NCT number NCT00105417
Title Interluekin-7 to Treat HIV-Infected People Receiving Antiretroviral Treatment
Official title A Phase I, Randomized, Placebo-Controlled, Double-Blind Study Evaluating the Safety of Subcutaneous Single Dose Interleukin-7 in HIV-1-Infected Subjects Who Are Receiving Antiretroviral Treatment (A5214)
Lead sponsor National Institute of Allergy and Infectious Diseases (NIAID), NIH
Status Completed
Phase Phase 1
Study type Interventional
Conditions HIV Infections, HIV
Intervention type Drug
Interventions IL-7
Enrollment 20
Start date Mar 1, 2005
Completion May 1, 2006
First posted Mar 14, 2005
Last update posted Mar 4, 2008
Countries United States

At a glance

  • 1–9 Study sites
  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies